Overview

The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine the safety and tolerance of hyperimmune anti-HIV intravenous immunoglobulin (HIVIG) and of zidovudine (AZT) in infants with established HIV infection; to get preliminary evidence for the effectiveness of this type of treatment in preventing the advance of disease in HIV infected infants. HIVIG may be an effective agent that either alone or in combination with AZT will prevent progression of clinical disease.

Phase:

Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators:

Abbott
Glaxo Wellcome

Treatments:

Antibodies
gamma-Globulins
Immune Sera
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Zidovudine